Shares of Asian drugmakers drop after Trump threatens tariffs

U.S. President Donald Trump announced a 100% tariff on imported branded pharmaceuticals effective October 1, unless manufacturers have commenced U.S. production, triggering declines across Asian drugmaker shares including a 2.58% drop in Hong Kong's Hang Seng Biotech Index. This move, characterized by analysts as a durable sectoral tariff, is projected to elevate the global effective tariff rate to 18%, though its broader economic impact on certain regions like Japan and Australia is expected to be contained.

Analysis

The U.S. administration has threatened a significant escalation in trade policy, proposing a 100% tariff on imported branded pharmaceuticals effective October 1. This measure specifically targets companies that have not initiated manufacturing operations within the United States, creating a clear and immediate risk for drugmakers with U.S.-centric export models. The market reaction has been swift and negative across Asia, with Hong Kong's Hang Seng Biotech Index falling 2.58% and notable declines in shares of South Korean firms like Samsung Biologics (-1.6%) and Japanese firms like Sumitomo Pharma (-4.3%). However, the market is differentiating, rewarding companies with established or newly acquired U.S. footprints; Celltrion, for instance, rose 1.3% after announcing a $330 million acquisition of a U.S. entity from Eli Lilly. Analysts view these sectoral tariffs as more legally durable than prior measures and project they will contribute to raising the U.S. government's global effective tariff rate from approximately 10% to 18%, signaling a sustained protectionist stance. While the broader economic impact on nations like Japan is forecast to be limited, the direct threat to pharmaceutical supply chains and profitability is substantial.

Key Decisions for Investors

• Investors should immediately review their holdings in non-U.S. pharmaceutical companies to quantify exposure to firms lacking a significant U.S. manufacturing presence, as these are most at risk from the announced 100% tariff.
• Consider reallocating capital towards pharmaceutical companies with established U.S. operations or those, like Celltrion, actively pursuing U.S. acquisitions, as the market is clearly rewarding firms insulated from this specific trade policy risk.
• Monitor company announcements for capital expenditure plans related to U.S. manufacturing facilities before the October 1 deadline, as such commitments will be a key catalyst for individual stock re-ratings within the sector.